Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

From: li3511	5/7/2018 8:58:19 AM
	20 Recommendations Read Replies (1) of 63276

This article is about 10 months old, and it covers material presented in part at the annual meeting of the American Association for Cancer Research (2016) and the San Antonio Breast Cancer Symposium (2015). However, it just popped up recently on my newsfeed. clincancerres.aacrjournals.org In summary, studies in petri dishes and mice suggest that combining IMMU-132 with other drugs already on the market [Lynparza (Olaparib), Rubraca (Rucaparib), and Talazoparib (in development by Pfizer)] is more effective than either agent alone for TNBC. While the ASCENT trial (Phase 3 registration trial) has to use IMMU-132 as a monotherapy, if AA is received, clinicians outside of the trial are under no such constraint.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next